Although Stelara and Entyvio demonstrated similar cardiovascular safety profiles among older patients with inflammatory bowel ...

SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness ...

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

Ulcerative colitis is a chronic, immune-mediated disorder of the colon and rectum characterized by mucosal inflammation that damages the bowel wall surface. Current therapeutic options include ...

For older adults with inflammatory bowel disease (IBD), there was no significant difference in the risk of major ...

Dr. Gunn added, “Given QBECO SSI’s novel immunological mechanism and the growing interest in the role of senescence in the progression of aging and chronic disease, these data suggest that clearing ...

A preliminary modeling study suggests that four variables accessible at discharge could predict the risk for 90-day ...

PORTLAND, OR, UNITED STATES, February 7, 2025 /EINPresswire / -- The global ulcerative colitis (UC) market is ex ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...

The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus ...